RU2015143270A - Метадихол - жидкие и гелевые нанолекарственные препараты - Google Patents
Метадихол - жидкие и гелевые нанолекарственные препараты Download PDFInfo
- Publication number
- RU2015143270A RU2015143270A RU2015143270A RU2015143270A RU2015143270A RU 2015143270 A RU2015143270 A RU 2015143270A RU 2015143270 A RU2015143270 A RU 2015143270A RU 2015143270 A RU2015143270 A RU 2015143270A RU 2015143270 A RU2015143270 A RU 2015143270A
- Authority
- RU
- Russia
- Prior art keywords
- subject
- disease
- specified
- level
- water
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
Claims (17)
1. Водно-гелевый состав, имеющий существенные водобарьерные свойства, причем указанный гель содержит
a) водорастворимый полимер;
b) наночастицы метадихола в терапевтически эффективной концентрации и
c) воду,
причем указанный гель не содержит пленкообразующего полимера, окклюзионных жиров или масел.
2. Состав по п. 1, где указанный водорастворимый полимер представляет собой карбопол.
3. Способ лечения кожного заболевания у субъекта, включающий местное введение указанному субъекту указанного геля по п. 1 в терапевтически эффективном количестве, где указанное кожное заболевание выбрано из группы, состоящей из воспалительных и гиперпролиферативных дерматологических заболеваний, кожных манифестаций заболеваний, являющихся иммунологическими по этиологии, таких как псориаз, атопический дерматит, контактный дерматит и другие экзематозные дерматиты, себорейный дерматит, нейродерматит, пролежень, красный плоский лишай, обыкновенная пузырчатка, пузырчатый пемфигоид, буллезный эпидермоз, уртикария, ангионевротические отеки, васкулит, эритема, кожная эозинофилия, эритематозная волчанка, экзема и МРЗС, базальноклеточная карцинома, со снижением тем самым тяжести заболевания.
4. Способ по п. 3, где указанное заболевание представляет собой инфекцию МРЗС.
5. Способ по п. 3, где указанное заболевание представляет собой экзему.
6. Способ по п. 3, где субъектом является человек.
7. Способ лечения заболевания путем улучшения физиологического или метаболического параметра у субъекта, при этом указанный способ предусматривает введение указанному субъекту терапевтически эффективного количества фармацевтического состава, содержащего наночастицы метадихола, причем указанный параметр представляет собой элемент, выбранный из повышения уровней сывороточного белка апоА-1 у указанного субъекта, снижения липопротеин (а) (ЛП(а)) у указанного субъекта, повышения уровня гемоглобина у указанного субъекта, повышения количества тромбоцитов у указанного субъекта, снижения уровня мочевой кислоты у указанного субъекта, регулирования уровня рСКФ у указанного субъекта, регулирования элемента, выбранного из абсолютного содержания нейтрофилов, абсолютного содержания моноцитов и уровня лейкоцитов у указанного субъекта; снижения повышенных отношений АСТ : АЛТ у указанного субъекта, снижения уровня ферритина у указанного субъекта, снижения уровня билирубина у указанного субъекта, регулирования уровня гормона щитовидной железы (ТТГ) у указанного субъекта и снижения уровня элемента, выбранного из уровней ПТГ, кальция, креатинина, щелочной фосфатазы, АМК и уровней фосфора в сыворотке крови, у субъекта с регулированием тем самым указанного параметра у указанного субъекта.
8. Способ по п. 7, где указанное заболевание представляет собой заболевание почек.
9. Способ по п. 7, где указанное заболевание представляет собой инфекцию МРЗС.
10. Способ по п. 7, где указанное заболевание представляет собой МДС.
11. Способ по п. 7, где указанное заболевание представляет собой гематологическое заболевание.
12. Способ по п. 7, где указанное заболевание представляет собой рак предстательной железы.
13. Способ по п. 7, где субъектом является человек.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361794490P | 2013-03-15 | 2013-03-15 | |
| US61/794,490 | 2013-03-15 | ||
| PCT/US2014/023777 WO2014150609A1 (en) | 2013-03-15 | 2014-03-11 | Metadichol r liquid and gel nanoparticle formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017116682A Division RU2736752C2 (ru) | 2013-03-15 | 2014-03-11 | Метадихол - жидкие и гелевые нанолекарственные препараты |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015143270A true RU2015143270A (ru) | 2017-04-27 |
| RU2631600C2 RU2631600C2 (ru) | 2017-09-25 |
Family
ID=51530033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017116682A RU2736752C2 (ru) | 2013-03-15 | 2014-03-11 | Метадихол - жидкие и гелевые нанолекарственные препараты |
| RU2015143270A RU2631600C2 (ru) | 2013-03-15 | 2014-03-11 | Метадихол® - жидкие и гелевые нанолекарственные препараты |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017116682A RU2736752C2 (ru) | 2013-03-15 | 2014-03-11 | Метадихол - жидкие и гелевые нанолекарственные препараты |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9006292B2 (ru) |
| EP (1) | EP2968209B1 (ru) |
| JP (2) | JP5996146B2 (ru) |
| KR (1) | KR101700949B1 (ru) |
| CN (1) | CN105188687B (ru) |
| AU (1) | AU2014235779B2 (ru) |
| BR (1) | BR112015011379B1 (ru) |
| CA (1) | CA2894370C (ru) |
| DK (1) | DK2968209T3 (ru) |
| HK (1) | HK1212247A1 (ru) |
| MX (1) | MX359686B (ru) |
| RU (2) | RU2736752C2 (ru) |
| SG (1) | SG11201506430XA (ru) |
| WO (1) | WO2014150609A1 (ru) |
| ZA (1) | ZA201505436B (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11554087B2 (en) | 2020-11-05 | 2023-01-17 | The Gillette Company Llc | Shaving aid comprising an antioxidant |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4670471A (en) | 1981-11-03 | 1987-06-02 | Clark Lealand L | Treatment for inflammatory skin disease |
| US20090191288A1 (en) * | 1996-02-12 | 2009-07-30 | Squires Meryl J | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases |
| US20030198616A1 (en) * | 2002-04-23 | 2003-10-23 | Combe Incorporated | Moisturizing skin gel and method |
| JP4533134B2 (ja) * | 2002-06-10 | 2010-09-01 | エラン ファーマ インターナショナル，リミティド | ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ |
| ITMI20031313A1 (it) * | 2003-06-27 | 2004-12-28 | Indena Spa | Associazioni di agenti vasoprotettori e formulazioni che li contengono. |
| US7217546B1 (en) * | 2003-07-01 | 2007-05-15 | Sami Labs Ltd | Commercially viable process for high purity of fatty alcohol C24 to C36 and its cosmetic application for skin hair and nails |
| US20050074443A1 (en) * | 2003-10-03 | 2005-04-07 | Treadwell Benjamin V. | Methods of attenuating autoimmune disease and compositions useful therefor |
| US20100063004A1 (en) * | 2006-12-04 | 2010-03-11 | Ranjan Ray Chaudhuri | Topical pharmaceutical composition |
| US8722093B2 (en) * | 2009-02-23 | 2014-05-13 | NanoRx, Inc. | Policosanol nanoparticles |
| CA2776474C (en) * | 2009-10-02 | 2021-01-12 | Foamix Ltd. | Topical tetracycline compositions |
| WO2012027159A1 (en) * | 2010-08-23 | 2012-03-01 | NanoRx, Inc. | Policosanol nanoparticles |
| US20130045179A1 (en) | 2011-08-15 | 2013-02-21 | Mihai Ciustea | Combination therapy and methods for treatment and prevention of hyperproliferative diseases |
-
2014
- 2014-03-11 CA CA2894370A patent/CA2894370C/en active Active
- 2014-03-11 AU AU2014235779A patent/AU2014235779B2/en active Active
- 2014-03-11 WO PCT/US2014/023777 patent/WO2014150609A1/en active Application Filing
- 2014-03-11 US US14/205,243 patent/US9006292B2/en active Active
- 2014-03-11 SG SG11201506430XA patent/SG11201506430XA/en unknown
- 2014-03-11 KR KR1020157020035A patent/KR101700949B1/ko active IP Right Grant
- 2014-03-11 CN CN201480016205.7A patent/CN105188687B/zh active Active
- 2014-03-11 BR BR112015011379-6A patent/BR112015011379B1/pt active IP Right Grant
- 2014-03-11 RU RU2017116682A patent/RU2736752C2/ru active
- 2014-03-11 MX MX2015008676A patent/MX359686B/es active IP Right Grant
- 2014-03-11 EP EP14770019.9A patent/EP2968209B1/en active Active
- 2014-03-11 JP JP2016501340A patent/JP5996146B2/ja active Active
- 2014-03-11 DK DK14770019.9T patent/DK2968209T3/da active
- 2014-03-11 RU RU2015143270A patent/RU2631600C2/ru active
-
2015
- 2015-07-28 ZA ZA2015/05436A patent/ZA201505436B/en unknown
-
2016
- 2016-01-13 HK HK16100350.6A patent/HK1212247A1/xx unknown
- 2016-07-12 JP JP2016137526A patent/JP6346918B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5996146B2 (ja) | 2016-09-21 |
| BR112015011379A2 (ru) | 2017-08-22 |
| JP2016512827A (ja) | 2016-05-09 |
| CN105188687B (zh) | 2018-05-01 |
| MX2015008676A (es) | 2016-04-25 |
| DK2968209T3 (da) | 2021-01-04 |
| ZA201505436B (en) | 2016-07-27 |
| KR20150127575A (ko) | 2015-11-17 |
| RU2017116682A (ru) | 2018-10-23 |
| US20140275285A1 (en) | 2014-09-18 |
| AU2014235779A1 (en) | 2015-09-03 |
| CA2894370C (en) | 2016-01-12 |
| KR101700949B1 (ko) | 2017-01-31 |
| EP2968209B1 (en) | 2020-12-16 |
| US9006292B2 (en) | 2015-04-14 |
| CN105188687A (zh) | 2015-12-23 |
| HK1212247A1 (en) | 2016-06-10 |
| BR112015011379B1 (pt) | 2022-10-11 |
| EP2968209A1 (en) | 2016-01-20 |
| JP2017008057A (ja) | 2017-01-12 |
| EP2968209A4 (en) | 2016-11-02 |
| WO2014150609A1 (en) | 2014-09-25 |
| RU2631600C2 (ru) | 2017-09-25 |
| MX359686B (es) | 2018-10-05 |
| SG11201506430XA (en) | 2015-09-29 |
| RU2017116682A3 (ru) | 2020-06-03 |
| CA2894370A1 (en) | 2014-09-25 |
| AU2014235779B2 (en) | 2015-11-26 |
| JP6346918B2 (ja) | 2018-06-20 |
| RU2736752C2 (ru) | 2020-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012040073A3 (en) | Biomarkers of renal injury | |
| WO2012174282A3 (en) | Biomarker compositions and methods | |
| WO2013134786A3 (en) | Biomarker compositions and methods | |
| WO2013022995A3 (en) | Biomarker compositions and methods | |
| RU2015143270A (ru) | Метадихол - жидкие и гелевые нанолекарственные препараты | |
| JP2016518510A5 (ru) | ||
| CN105497915A (zh) | miR-223-3p或miR-885-5p模拟物在制备治疗急性痛风性关节炎药物中的应用 | |
| IN2014CN04615A (ru) | ||
| Akalin et al. | Prognostic importance of fibroblast growth factor-23 in dialysis patients | |
| EP2628762A3 (de) | Verfahren zur Herstellung von Polyphenoldisulfiden | |
| PL428992A1 (pl) | Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą | |
| CN110251737A (zh) | 一种添加了玻尿酸的乳胶避孕套 | |
| Zemlyankin | Cows blood indices with hypofunction of ovaries and chronic endometritis | |
| Yi et al. | Association Between Compliance with Visiting Nephrologist and Clinical Outcomes of Remote Peritoneal Dialysis Patients | |
| WO2011124884A3 (en) | Methods for categorising cancer such as breast cancer | |
| RU2449284C1 (ru) | Способ постмортальной диагностики острого нарушения мозгового кровообращения | |
| Zhu et al. | Association of residual renal function at initiation of dialysis with prognosis in maintenance dialysis patients | |
| Abdallah et al. | THE RELATIONSHIP BETWEEN SERUM PARAOXONASE ACTIVITY AND EPICARDIAL ADIPOSE TISSUE IN HEMODIALYSIS PATIENTS | |
| Prytkova | Interleukin-6 Dynamics as a Predictor of the Renal Dysfunction Formation and a Criterion of the Effectiveness of the Nephroprotective Strategy in Early Rheumatoid Arthritis | |
| Semydotska et al. | RENAL RISCS IN DETERMINATION OF BRONCHIAL ASTHMA PHENOTYPES | |
| Khoshvaghti et al. | The effect of vitamin E and selenium on treatment process, serum malondialdehyde and vitamin D levels of cows with mastitis | |
| Akhmedov et al. | Variation in the Clinical Manifestation of Rheumatoid Arthritis Based on the Residence Areas | |
| RU2592239C1 (ru) | Метод определения ненасыщенных жирных кислот в эритроцитах периферической крови | |
| Livanov et al. | Optimization of Intensive Care of Patients with Delirium Tremens | |
| CN1634127A (zh) | 外用剂药用组合物及应用 |